Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115333 · ClinicalTrials.gov registry record · NA
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
A NA study of Recurrent Glioblastoma and Gliosarcoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT03115333 is a NA study of Recurrent Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 146 participants, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03115333, a NA study of Recurrent Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Study Locations (20)
Florida
- Boca Raton Regional Hospital - Boca Raton
- Baptist MD Anderson Cancer Center - Jacksonville
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt Cancer Center - Tampa
California
- Eden Hospital Medical Center - Castro Valley
- Loma Linda University Medical Center - Loma Linda
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- VA Palo Alto Health Care System - Palo Alto
Arizona
- Saint Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Northside Hospital - Atlanta
- Northside Hospital-Forsyth - Cumming
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- IU Health Methodist Hospital - Indianapolis
Kentucky
- Baptist Health Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2027-05-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03115333
The ClinicalTrials.gov registry entry for NCT03115333 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (118% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging is the first listed.
NCT03115333 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03115333 about?
NCT03115333 is a clinical study titled "DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma". This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blo...
What is the current status of trial NCT03115333?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 146 participants. The study started on 2017-07-25. Estimated completion is 2027-05-07.
What conditions does trial NCT03115333 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT03115333?
The interventions under investigation include: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03115333?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03115333 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
RECRUITING · NA
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
Mathematical Model-Adapted Radiation In Glioblastoma
COMPLETED · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.